Yahoo · Oct 30, 2026
BridgeBio's Heart Disorder Drug Attruby Faces Unanticipated Near-Term Tailwinds, UBS Says
BridgeBio Pharma's (BBIO) heart disorder drug Attruby faces near-term tailwinds from the likely appr
NYSE · UNH
UNITEDHEALTH GROUP INCORPORATED (Delaware)
Healthcare · Medical - Healthcare Plans
$410.91
Down-$3.94 (-0.96%)
Updated Oct 30, 2026, 10:52 PM
SID Score
7.7/10
Composite research score
Smart Money
41/100
Neutral
- Market cap
- 305B
- P/E ratio
- 17.38
- Dividend yield
- 2.12%
- 52-week range
- $255.97 – $461.62
- Volume
- 3.8M
- Avg. volume
- 8.77M
Price performance · UNH
UNH price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
UNH closed at $410.91 after 21 trading sessions, up 12.52% for the selected period.
- Last close
- $410.91
- Period change
- +12.52%
- Period low
- $365.20
- Period high
- $424.98
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $413.71 | $414.76 | $404.31 | $410.91 | 3.8M |
| Oct 28, 2026 | $407.00 | $416.19 | $405.00 | $407.10 | 3.9M |
| Oct 27, 2026 | $412.72 | $413.5975 | $408.22 | $410.39 | 3.75M |
| Oct 26, 2026 | $418.99 | $420.8599 | $408.35 | $410.70 | 4.59M |
| Oct 23, 2026 | $424.30 | $425.25 | $416.37 | $418.09 | 3.89M |
| Oct 22, 2026 | $418.38 | $426.55 | $417.13 | $424.98 | 5.42M |
| Oct 21, 2026 | $421.80 | $421.80 | $415.00 | $417.00 | 3.99M |
| Oct 20, 2026 | $410.12 | $422.40 | $408.28 | $419.26 | 6.82M |
| Oct 19, 2026 | $399.69 | $408.50 | $399.20 | $406.88 | 5M |
| Oct 16, 2026 | $410.35 | $412.37 | $395.5175 | $401.43 | 8.11M |
| Oct 15, 2026 | $401.24 | $414.12 | $400.00 | $406.67 | 10.16M |
| Oct 14, 2026 | $382.29 | $396.44 | $382.29 | $395.62 | 7.77M |
| Oct 13, 2026 | $397.625 | $399.88 | $372.80 | $377.76 | 12.65M |
| Oct 12, 2026 | $382.98 | $382.98 | $373.67 | $378.52 | 5.91M |
| Oct 9, 2026 | $373.94 | $387.52 | $373.02 | $379.30 | 7.47M |
| Oct 8, 2026 | $375.38 | $376.45 | $368.50 | $370.95 | 7.29M |
| Oct 7, 2026 | $375.92 | $383.48 | $372.01 | $375.98 | 5.63M |
| Oct 6, 2026 | $379.03 | $380.41 | $373.70 | $376.32 | 5.04M |
| Oct 5, 2026 | $372.33 | $379.14 | $368.0501 | $378.58 | 5.83M |
| Oct 2, 2026 | $365.14 | $372.68 | $364.47 | $371.90 | 3.31M |
| Oct 1, 2026 | $367.99 | $371.86 | $362.60 | $365.20 | 3.94M |
Latest UNH news
The latest Smart Investors Daily articles mentioning UNH.
Stock researchCompany · Overview
Company
Market Activity
Research & News
UNH research
Overview
Company profile and research snapshot.
Company profile
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $387.80
- Implied upside
- —
- Analysts
- 20
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 27, 2026 | Wells Fargo | Overweight | — |
| Oct 27, 2026 | Morgan Stanley | Overweight | — |
| Oct 22, 2026 | Mizuho | Outperform | — |
| Oct 20, 2026 | RBC Capital | Outperform | — |
| Oct 16, 2026 | JP Morgan | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 30, 2026
1 safe-and-steady stock to research further and 2 we find risky
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Yahoo · Oct 30, 2026
BrightSpring Soars 12% on Q3 Beat and Raised 2026 Guidance as Adjusted EBITDA Jumps 42%
Key TakeawaysBrightSpring Health Services stock jumped 12% as adjusted EBITDA rose 42% and 2026 guidance went up. Gross profit per script rose 27% in what management calls the peak year for Medicare’s drug-price negotiations.
Yahoo · Oct 30, 2026
As the Nasdaq wobbles on capex, this Buffett strategy went 15-for-15
Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
AI research layers
Interpretive context generated from the platform’s current data sources.
UnitedHealth Group Stock Performance
UnitedHealth Group shares traded at $410.91, reflecting a daily decline of approximately 1.02%, per SID market data. Over the trailing one-month period, the stock gained 8.58%, while the three-month return registered a negative 3.41%, indicating recent volatility following a strong short-term recovery. On a twelve-month basis, UNH posted a gain of 19.03%. The stock currently trades above both its 50-day moving average of $389.31 and its 200-day moving average of $359.80, according to Massive/Polygon technical data. The 14-day relative strength index stands at 70.1, placing the stock at the upper boundary of neutral territory near overbought conditions. UNH carries a beta of 0.432, underscoring its historically lower volatility relative to the broader market. Average daily trading volume stands at approximately 8.77 million shares, supporting consistent liquidity for institutional participants.
UnitedHealth Group Valuation Analysis
UnitedHealth Group currently carries a market capitalization of approximately $305 billion, per SID market data, maintaining its position as the largest publicly traded healthcare company. The stock trades at a price-to-earnings ratio of 17.38, which remains moderate relative to large-cap healthcare peers, according to SEC filings and reported financial data. The price-to-book ratio stands at 3.19, reflecting a premium valuation on shareholder equity. Notably, the PEG ratio registers at negative 1.02, suggesting that forward earnings growth estimates have shifted into negative territory, a factor that warrants attention in the context of the company's recent guidance adjustments. UNH offers a dividend yield of approximately 2.59%, providing an income component for shareholders. Within the broader healthcare sector, these valuation metrics position UnitedHealth as a mature, cash-generating enterprise trading at a reasonable earnings multiple but facing questions around near-term growth trajectory.
Smart Money Activity for UNH
UnitedHealth Group's composite smart money score stands at 41 out of 100, registering a neutral signal, per SID market data. The institutional component scores a maximum 25 out of 25, indicating robust and sustained institutional ownership and accumulation across major fund holders, according to 13F institutional filings. Dark pool activity scores 12.2 out of 25, suggesting moderate levels of off-exchange block trading. Congressional trading activity registers at 4.0 out of 25, reflecting limited recent legislative member transactions. The insider component scores 0.0 out of 25; however, SEC Form 4 filings reveal 20 insider transactions over the past 90 days, all of which were purchases with zero insider sales recorded during the period. This unanimously bullish insider buying pattern is notable, as it signals confidence from company executives and directors despite the stock's recent price volatility. The divergence between the low insider score and strong buying activity may reflect timing or transaction size factors within the scoring methodology.
UnitedHealth Group Earnings Outlook
UnitedHealth Group has delivered consecutive earnings surprises across its three most recent reporting periods, according to company earnings reports. In the quarter reported on April 21, 2026, UNH posted earnings per share of $7.23 against a consensus estimate of $6.56, representing a positive surprise of $0.67. The July 16, 2026 quarter produced the most significant beat, with actual EPS of $6.38 versus estimates of $4.85, a $1.53 upside surprise. The October 13, 2026 quarter showed actual EPS of $4.69 compared to the $4.14 estimate, a $0.55 beat. The upcoming quarter, with results expected on October 27, 2026, carries an analyst consensus estimate of $4.14 per share. The pattern of consistent outperformance against estimates demonstrates operational execution, though the sequential decline in absolute EPS figures across recent quarters reflects typical seasonal patterns within UnitedHealth's diversified healthcare services business.
Wall Street Analyst Ratings for UNH
Wall Street consensus on UnitedHealth Group remains uniformly positive, with all five most recent analyst actions maintaining bullish ratings, per SID consensus data. On October 27, 2026, both Wells Fargo and Morgan Stanley reiterated their Overweight ratings on UNH, signaling continued conviction following the company's latest quarterly results. Mizuho maintained its Outperform rating on October 22, while RBC Capital reiterated its Outperform designation on October 20, according to Wall Street analyst reports. JP Morgan reaffirmed its Overweight rating on October 16, 2026. Notably, none of the five recent analyst actions involved a downgrade or rating change; all represented maintenance of pre-existing positive positions. The absence of any Hold, Underweight, or Sell ratings among recent coverage updates reflects broad institutional confidence in UNH's business fundamentals. This unanimous bullish alignment across major investment banks provides a consistent directional signal for institutional and retail market participants evaluating the stock.
